Official Title
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
Brief Title
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
Protocol ID
NCT04525209
Lead Sponsor
Ruijin Hospital
Brief Summary
A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics
will be carried out. In this study, clinical specimens of resected PDAC collected by our
research group from 2017 to 2019 will be selected as research objects.Tumor tissues and
their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used
for genome, transcriptome sequencing and mass spectrometry analysis of proteome and
phosphorylated proteome.Combined with the data results of multiomics, bioinformatics
analysis and network database information, we will clarify the relationship between
multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer
proteome. A molecular landscape of the progression of pancreatic cancer at the
genome-transcriptome-proteome level provides new therapeutic targets to improve the
prognosis of this deadly disease.
Study Period
-
Enrollment Count
200 participants
Eligibility Criteria
Inclusion Criteria:
1. The diagnosis of pancreatic cancer was confirmed by histological examination or fine
needle aspiration cytology;
2. The tumor was graded according to THE WHO standard, and the tumor stage was graded
according to the TNM stage;
Exclusion Criteria:
1. The inclusion criteria of the above groups were not met;
2. There are few tissue specimens, only enough for clinical diagnosis;
3. Patients are unwilling to conduct follow-up study;
4. For the new diagnosed patient, radiotherapy or chemotherapy have been given in the
previous three months;
Filters
Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics
UNKNOWN
ADULT
OLDER_ADULT